Showing results (1-10 of 665) with videos related to
Sort By:
Pageof 67
Clinical Pharmacology and Therapeutics|September 11, 2023
Population Pharmacokinetics and Pharmacodynamics of Pegozafermin in Patients with Nonalcoholic SteatohepatitisChih-Ming Leo Tseng, Kemal Balic, R Will Charlton, et al.Alimentary Pharmacology & Therapeutics|September 18, 2023
Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitisNaim Alkhouri, Donald Lazas, Rohit Loomba, et al.The Journal of Pharmacology and Experimental Therapeutics|August 10, 2023
The Novel GlycoPEGylated FGF21 Analog Pegozafermin Activates Human FGF Receptors and Improves Metabolic and Liver Outcomes in Diabetic Monkeys and Healthy Human VolunteersMoti Rosenstock, Leo Tseng, Andrew Pierce, et al.The Lancet. Gastroenterology & Hepatology|December 15, 2022
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose studyRohit Loomba, Eric J Lawitz, Juan Pablo Frias, et al.The New England Journal of Medicine|June 25, 2023
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASHRohit Loomba, Arun J Sanyal, Kris V Kowdley, et al.Journal of Hepatology|December 6, 2017
Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directionsRohit LoombaCureus|January 1, 2016
Thrombocytosis in the Setting of Isomerism and a Functionally Univentricular HeartRohit LoombaNeurology|August 12, 2004
Predicting the response to sumatriptan: the Sumatriptan Naratriptan Aggregate Patient DatabaseHans Christoph-Diener, Michel Ferrari, Hank Mansbach, et al.Seminars in Liver Disease|February 23, 2018
Can Elastography Differentiate Isolated Fatty Liver from Nonalcoholic Steatohepatitis?Veeral Ajmera, Rohit LoombaCurrent Treatment Options in Gastroenterology|March 15, 2021
An update on the role of the microbiome in non-alcoholic fatty liver disease pathogenesis, diagnosis, and treatmentMarialena Mouzaki, Rohit LoombaPageof 67